



Investigator Initiated Drug Research Program


Maneesh Kumar, MD, PhD
Scientific Program Manager

September 27, 2016

Drug Research Program

- Pfizer and BCRF launch new partnership
 - RFP launched March 1
 - Partnership with TBCRC
 - Proposals reviewed and identified for funding by November 1
- Goal is to fund independent, innovative and high-quality, investigator-initiated research
 - Clinical trials managed by the TBCRC (funding for clinical trial conduct and correlates)
 - Pre-clinical, mechanism of action and similar studies managed by BCRF
- \$15-million over 3 years for BCRF to launch an independent, high-quality investigator-initiated drug research programs
 - Access to 16 study drugs at no cost that can be used in human studies
 - Additional Pfizer agents may be added over time
- Additional companies under discussion to join BCRF

Investigator Initiated Research Programs



BCRF Investigator Initiated Research Program



Response

- “This is AMAZING for patients! Groundbreaking! Congratulations.”
- “I’m so proud of BCRF’s work! This is wonderful news. Congratulations on the collaboration, what a good idea!”
- “I think this partnership between BCRF and pharmaceutical pipelines is a progressive step forward in preclinical and clinical research [that will benefit patients].”
- “It is a fantastic mechanism and bridges a super important gap.”
- “I think this is a wonderful funding mechanism to help support translational drug development. Kudos to BCRF and Pfizer for putting together this program.”



BCRF NEWS
SCIENCE NEWS

BCRF Launches New Drug Research Collaborative

By BCRF | February 22, 2016

A recent article in The Wall Street **Breast Cancer**,” (published Feb. 1 research today. One of the greatest treatments is the lack of funding to

As the largest nonprofit funder of I actively combatting this issue by I specifically devoted to bridging the access to drugs in development. I from Pfizer, researchers will also I approved products and its pipeline program grows, we hope to see of propel research forward, faster.

“This research effort speaks to the supports some of the brightest mit **Larry Norton, M.D.**, BCRF Scientist H. Lauder Breast Center at Memo encourage more creative, academ access to clinical trials. We believ greatly accelerate and impact reser breakthrough discoveries.”

MENU

BREAST CANCER

BCRF: Funding the Path to Prevention and Cure

Share Pin Email



Researcher in Lab. Getty Images



By **Jean Campbell, MS**
Updated August 01, 2016

Research is an ongoing critical need if breast cancer prevention and cure are to become realities. Breast cancer research is not only supported by federal

THE ASCO POST NEWS MEET

Breast Cancer Research Foundation: Revitalizing Academic Research in Breast Cancer Through Drug Research Collaborative



When **Evelyn H. Lauder** was diagnosed with breast cancer in 1989, she became a vocal spokesperson for women’s health, and in 1993, along with **Larry Norton, MD**, now Deputy Physician-in-Chief for Breast Cancer Programs and Medical Director of the Evelyn H. Lauder Breast Center at Memorial Sloan Kettering Cancer Center, founded the Breast Cancer Research Foundation (BCRF), which has since raised more than half-a-billion dollars for research. This year, the BCRF is providing \$54 million to fund 240 research projects in 13 countries, making the foundation the largest nonprofit funder of breast cancer research in the world.

“Today, the average lifespan of a person with metastatic disease is 3 years. We want

verywell

Search

announced an expansion of its h a new collaborative breast cancer d the BCRF Investigator-Initiated m. The expanded program is intended ven academic investigators and their nary and metastatic breast cancers. n grant from Pfizer Oncology. : portfolio of drugs approved by the elopment pipeline.

of the BCRF and Chair of the Drug Research Program and what may for metastatic disease.

ost goals you hope to achieve?

rest cancer. More specifically, my re the goals of their specific research that, hopefully, will help us answer re it We are funding 240 scientists in

Challenges

- Reputational Risk
- Influence and Review
- Intellectual Property
- Logistics and Partnerships

THANK YOU

TOGETHER WE CAN SEE A WORLD WITHOUT BREAST CANCER

#BeTheEnd

Breast Cancer Research Foundation